Deaths during study
| . | BSC (n = 229) . | Tipifarnib (n = 225) . |
|---|---|---|
| Deaths, n (%)* | 98 (43) | 91 (40) |
| Cause of death | ||
| Progressive disease, n (%) | 59 (26) | 41 (18) |
| Adverse events, n (%) | 35 (15) | 43 (19) |
| Drug-related adverse events, n (%)† | 0 | 4 (2) |
| Other, n (%)‡ | 4 (2) | 7 (3) |
| . | BSC (n = 229) . | Tipifarnib (n = 225) . |
|---|---|---|
| Deaths, n (%)* | 98 (43) | 91 (40) |
| Cause of death | ||
| Progressive disease, n (%) | 59 (26) | 41 (18) |
| Adverse events, n (%) | 35 (15) | 43 (19) |
| Drug-related adverse events, n (%)† | 0 | 4 (2) |
| Other, n (%)‡ | 4 (2) | 7 (3) |
Includes deaths at any time during treatment, within 30 days after treatment termination, or before subsequent treatment, whichever was earlier.
Drug-related indicates possible, probable, or very likely related to trial medication as assessed by the investigator.
Other refers to deaths where the cause was unknown, probable cardiac failure, suspected infection, or probable gastrointestinal hemorrhage.